Answers are grounded in this paper and cite their sources.
This review details immune checkpoint inhibitors' effects on urological malignancies, indicating significant advancements in treatment options.
Immune checkpoint inhibitors (ICIs) represent the next leap in the management of urological malignancies. In urology, ICIs are already used extensively in renal cell carcinoma and to extent in bladder carcinoma and prostate carcinoma. In this review article, we will be looking into ICIs’ use in various urological malignancies, the latest trials, and protocols.
No takes yet. Share an insight, caveat, or question.
Prakash et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: